Third-party information liability disclaimer
Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.
The following documents contain the written submissions received by the Competition Bureau in response to its market study notice, which was issued on April 8, 2021. All submissions received as part of this consultation exercise are available to the public, except where confidentiality is specifically requested.
- Joint Submission by Hoffmann-La Roche Limited and Novartis Pharmaceuticals Canada Inc.
Comments: (HTML) (PDF; 223 KB; 11 Pages)
- Submission by Montreal Economic Institute
Comments: (HTML) (PDF; 623 KB; 8 Pages)
- Submission by The Canadian Medical Association
Comments: (HTML) (PDF; 226 KB; 9 Pages)
- Submission by Lifeworks
Comments: (HTML) (PDF, 102 KB, 2 Pages)
- Submission by GE Healthcare Canada
Comments: (HTML) (PDF; 170 KB; 4 Pages)
- Submission by Medtech Canada
Comments: (HTML) (PDF; 499 KB; 17 Pages)
- Submission by the Ontario Medical Association
Comments: (HTML) (PDF; 182 KB; 4 Pages)
If these documents are not accessible to you, please contact the Competition Bureau's Information Centre Toll free: 1-800-348-5358, Phone: 819-997-4282 TTY (hearing impaired): 1 866 694 8389 for alternate print formats.